Cyanocobalamin 50microgram tablets

Pays: Royaume-Uni

Langue: anglais

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingrédients actifs:

Cyanocobalamin

Disponible depuis:

Alliance Healthcare (Distribution) Ltd

Code ATC:

B03BA01

DCI (Dénomination commune internationale):

Cyanocobalamin

Dosage:

50microgram

forme pharmaceutique:

Oral tablet

Mode d'administration:

Oral

classe:

No Controlled Drug Status

Type d'ordonnance:

Valid as a prescribable product

Descriptif du produit:

BNF: 09010200

Notice patient

CYANOCOBALAMIN
50 MICROGRAMS TABLETS
Vitamin B
12
50 TABLETS
P
Each film coated tablet contains
50 micrograms cyanocobalamin.
Also contains lactose.
See leaflet for further information.
To be taken by mouth.
Use as directed by your doctor.
DOSAGE: Adults and Elderly -
Usual dose is 1 to 3 tablets or
more, daily between meals.
Children: Usual dose is 1 tablet.
Keep out of the sight and reach
of children.
Do not store above 25°C.
Store in the original container in
order to protect from light.
Keep the container tightly closed.
Marketing Authorisation Holder:
Mercury Pharma Group Ltd.,
Capital House,
85 King William Street,
London EC4N 7BL, UK
PL 10972/0028
LL-117965-01
50
MICROGRAMS
CYANOCOBALAMIN
50 MICROGRAMS TABLETS
Vitamin B
12
50 TABLETS
P
Each film coated tablet contains
50 micrograms cyanocobalamin.
Also contains lactose.
See leaflet for further information.
To be taken by mouth.
Use as directed by your doctor.
DOSAGE: Adults and Elderly - Usual
dose is 1 to 3 tablets or more, daily
between meals.
Children: Usual dose is 1 tablet.
Keep out of the sight and reach of
children.
Do not store above 25°C.
Store in the original container in
order to protect from light.
Keep the container tightly closed.
Marketing Authorisation Holder:
Mercury Pharma Group Ltd.,
Capital House,
85 King William Street,
London EC4N 7BL, UK
PL 10972/0028
LL-117965-01
11001620
50
MICROGRAMS
B.No :
Exp :
PREGNANCY, BREAST FEEDING AND FERTILITY
If you are pregnant or breast-feeding, think you may be pregnant or
are planning
to have a baby, ask your doctor or pharmacist for advice before taking
this
medicine.
As with all drugs Cyanocobalamin Tablets should only be given in
pregnancy
and when breast feeding if absolutely necessary.
CYANOCOBALAMIN TABLETS CONTAINS LACTOSE
This medicine also contains lactose (which is a sugar). If you have
been told by your
doctor that you have an intolerance to some sugars, contact your
doctor before taking
this medicinal product.
3. HOW TO TAKE CYANOCOBALAMIN TABLETS
Always take this medicine exactly as de

Résumé des caractéristiques du produit

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
_ _
Cytacon 50micrograms Tablets
Cyanocobalamin 50micrograms Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 50 micrograms Cyanocobalamin BP.
Excipient(s) with known effect
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Recommended Clinical Indications:
Treatment of nutritional Vitamin B
12
deficiency.
Treatment of vitamin B 12 deficiency following partial gastrectomy.
Treatment of tropical sprue, alone or with folic acid.
Treatment
of
pernicious
anaemia
when
parenteral
administration
is
not
possible or not advised.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Elderly:
The normal dose for adults is appropriate for the elderly.
Adults:
One to three tablets (50 to 150 micrograms) or more daily at the
discretion of the
physician.
In pernicious anaemia intramuscular therapy is preferable for initial
correction of
vitamin B12 deficiency. However, if necessary, the oral route may be
used to follow
this, in which case at least 300 micrograms should be given daily
Paediatric population:
One tablet (50 micrograms) daily at the discretion of the physician.
When possible,
This medicine
doses should be taken between meals.
Method of administration: Oral.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in
section 6.1.
Hypersensitivity to the product or any of the excipients.
4.4
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
For pernicious anaemia, an adequate dose must be used and the blood
picture
must be examined regularly at least every three months for 18 months
until
stabilised, and then annually.
Indiscriminate administration of this medicine may mask precise
diagnosis.
Patients with rare hereditary problems of galactose intolerance, total
lactase
deficiency or glucose-galactose malabsorption should not take this
medicine.
4.5
INTERACTIONS
WITH
OTHER
MEDICINAL
PRODUCTS
AND
OTHER
FORMS
OF